New drug shows promise for controlling blood pressure in rare hormone disorder
NCT ID NCT04605549
First seen Mar 08, 2026 · Last updated May 12, 2026 · Updated 8 times
Summary
This study tested a new drug called CIN-107 in 15 adults with primary aldosteronism, a condition where the body makes too much of a hormone that raises blood pressure. The goal was to see if the drug could safely lower blood pressure over 12 weeks, with a longer follow-up for safety. Participants stopped their usual blood pressure medicine before starting CIN-107. The study was small and early-stage, so more research is needed to confirm the results.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY ALDOSTERONISM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Greenbrae, California, 94904, United States
-
Research Site
San Francisco, California, 94110, United States
-
Research Site
West Hollywood, California, 90048, United States
-
Research Site
Chicago, Illinois, 60611, United States
-
Research Site
Baltimore, Maryland, 21287, United States
-
Research Site
Ann Arbor, Michigan, 48109, United States
-
Research Site
Rochester, Minnesota, 55905, United States
-
Research Site
Cincinnati, Ohio, 45245, United States
-
Research Site
Columbus, Ohio, 43210, United States
-
Research Site
Dallas, Texas, 75390-9047, United States
Conditions
Explore the condition pages connected to this study.